ROYALTIES AND REIMBURSEMENT. 6.1 The Licensee agrees to pay the IC a noncreditable, nonrefundable license issue royalty as set forth in Appendix C.
ROYALTIES AND REIMBURSEMENT. 6.01 Licensee agrees to pay to PHS a noncreditable, nonrefundable license issue royalty as set forth in Appendix C within thirty (30) days from the date that this Agreement becomes effective.
ROYALTIES AND REIMBURSEMENT. 6.1 The Licensee agrees to pay the NIH a noncreditable, nonrefundable license issue royalty as set forth in Appendix C.
ROYALTIES AND REIMBURSEMENT. 6.1 Licensee agrees to pay PHS a noncreditable, nonrefundable license issue royalty as set forth in Appendix C.
ROYALTIES AND REIMBURSEMENT. 6.1 Licensee agrees to pay PHS [*]
ROYALTIES AND REIMBURSEMENT. The Licensee agrees to pay the IC a noncreditable, nonrefundable license issue royalty as set forth in Appendix C. The Licensee agrees to pay the IC a minimum annual royalty as set forth in Appendix C. The Licensee agrees to pay the IC earned royalties as set forth in Appendix C. The Licensee agrees to pay the IC benchmark royalties as set forth in Appendix C. A patent or patent application licensed under this Agreement shall cease to fall within the Licensed Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: the application has been abandoned and not continued; the patent expires or irrevocably lapses; or the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or administrative agency. No multiple royalties shall be payable because any Licensed Products or Licensed Processes are covered by more than one of the Licensed Patent Rights. On sales of Licensed Products by the Licensee made in other than an arms‑length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arms‑length transaction, based on sales of like quantity and quality products on or about the time of this transaction. With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed Patent Rights and paid by the IC prior to the effective date of this Agreement, the Licensee shall pay the IC, as an additional royalty, within sixty (60) days of the IC’s submission of a statement and request for payment to the Licensee, an amount equivalent to the unreimbursed patent expenses previously paid by the IC. With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed Patent Rights and paid by the IC on or after the effective date of this Agreement, the IC, at its sole option, may require the Licensee: to pay the IC on an annual basis, within sixty (60) days of the IC's submission of a statement and request for payment, a royalty amount equivalent to these unreimbursed expenses paid during the previous calendar year(s); to pay these unreimbursed expenses directly to the law firm employed by the IC to handle these functions. However, in this even...
ROYALTIES AND REIMBURSEMENT. 6.1 Licensee agrees to pay PHS a noncreditable and nonrefundable amount as reimbursement for patent expenses associated with obtaining the Licensed Patent Rights as set forth in Appendix C.
ROYALTIES AND REIMBURSEMENT. 6.1 The Licensee will require each Sublicensee to pay Licensee, and Licensee agrees to pay IC a noncreditable, nonrefundable Sublicensee issue royalties as set forth in Appendix C.
ROYALTIES AND REIMBURSEMENT. 6.1 The Licensee agrees to pay the NIH a noncreditable, nonrefundable license royalty as set forth in Appendix C within one-hundred and eighty (180) days of achieving a Liquidity Event. This obligation shall survive any termination or expiration of the Agreement.
ROYALTIES AND REIMBURSEMENT. 6.01 Licensee agrees to pay to PHS a noncreditable, nonrefundable license issue royalty as set forth in Appendix C within thirty (30) days from the date that this Agreement becomes effective. NIH Office of Technology Transfer PHS PATENT LICENSE AGREEMENT - EXCLUSIVE MODEL 940110 - Page 5 - FINAL - MediChem Research, Inc. - May 5, 1995
